Adropin-overexpressing mice or systemic adropin treatment attenuates hepatic steatosis and insulin resistance in DIO (Kumar et al., 2008)Adropin-deficient mice exhibited dyslipidemia and insulin resistance (Gao et al., 2014)Adropin administrations improve glucose homeostasis and protect against DIO (Gao et al., 2019). This evidence concerns the gene ENHO and fatty liver disease.